Just as i predicted...... An annual report full of fluff and positivity.
How can they just keep pushing forward with statements like the below when they have basically run the company into the ground!!!!
Dr Jackie Fairley, Starpharma CEO, commented, “Starpharma made significant progress across its portfolio during the 2023 financial year."
SPL is still being run as a research company. SPL is no longer just a research company. Jackie's comments in this annual report are all focused on research areas. THIS IS THE REASON THE SP IS IN THE GUTTER. 17yrs of research done by JF and look at where we are.
SPL must appoint a new CEO ASAP and please do not appoint another researcher!
SPL Price at posting:
14.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)